Scientific Letters
Vol. 9 No. 1 (2017): Review, Original Articles, Case Reports
The Efficacy and Safety of Sofosbuvir Containing Regimen in the Treatment of Hcv Infection in Patients with Haemoglobinopathy
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: September 27, 2016
Accepted: November 14, 2016
Accepted: November 14, 2016
2153
Views
766
Downloads
645
HTML
Infectious diseases
Authors
Downloads
Download data is not yet available.
Citations
Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. Global Distribution and Prevalence of Hepatitis C Virus Genotypes. Hepatology (Baltimore, Md) 2015;61(1):77-87.
Hui CK, Monto A, Belaye T, Lau E, Wright TL. Outcomes of interferon and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases. Gut 2003;52(11):1644-1648.
Jazwinski AB, Muir AJ. Direct-Acting Antiviral Medications for Chronic Hepatitis C Virus Infection. Gastroenterology & Hepatology 2011;7(3):154-162.
Taherkhani R, Farshadpour F. Epidemiology of hepatitis C virus in Iran. World Journal of Gastroenterology : WJG 2015;21(38):10790-10810.
Barth H. Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade. World Journal of Hepatology 2015;7(5):725-737.
Mirmomen S, Alavian SM. Treatment of HCV Infection in Multitransfused Thalassemic Patients: Does Liver Iron Status Affect the Outcome of Response? Hepat Mon 2005;5(1):11-13.
Tabatabaei SV, Alavian SM, Keshvari M, Behnava B, Miri SM, Karimi Elizee P, Zamani F, Amini Kafiabad S, Gharehbaghian A, Hajibeigy B, Bagheri Lankarani K. Low Dose Ribavirin for Treatment of Hepatitis C Virus Infected Thalassemia Major Patients; New Indications for Combination Therapy. Hepat Mon 2012;12(6):372-381.
Hussein NR. Sofosbuvir-Containing Regimen for the Treatment of Hepatitis C Virus in a Patient With Sickle-Thalassemia: A First Case Report. International Journal of Infection 2016(Inpress).
Papadopoulos N, Deutsch M, Georgalas A, Poulakidas H, Karnesis L. Simeprevir and Sofosbuvir Combination Treatment in a Patient with HCV Cirrhosis and HbS Beta 0-Thalassemia: Efficacy and Safety despite Baseline Hyperbilirubinemia. Case Reports in Hematology 2016;2016:4.
Ethics Approval
Scientific letterSupporting Agencies
NAHow to Cite
“The Efficacy and Safety of Sofosbuvir Containing Regimen in the Treatment of Hcv Infection in Patients with Haemoglobinopathy” (2017) Mediterranean Journal of Hematology and Infectious Diseases, 9(1), p. e2017005. doi:10.4084/mjhid.2017.005.
